论文部分内容阅读
美国ＦＤＡ已批准进行基因治疗帕金森病的临床实验计划 ,这将是基因疗法首次用于帕金森病的人体试验 ,该项Ｉ期临床实验预计需要 6个月的时间。在此前进行的大量临床前动物实验中 ,该基因疗法能明显改善拟帕金森病模型大鼠的运动技能 ,并能防止多巴胺神经元的进一步损伤、减少
The FDA has approved a clinical trial of gene therapy for Parkinson’s disease, which will be the first human trial of gene therapy for Parkinson’s disease. It is estimated that Phase I clinical trials will take six months. In a large number of pre-clinical animal experiments conducted before, this gene therapy can significantly improve motor skills in rats with Parkinson’s disease and prevent further damage and decrease of dopamine neurons